Adaptimmune Therapeutics Future Growth
Future criteria checks 0/6
Adaptimmune Therapeutics's earnings are forecast to decline at 9.5% per annum while its annual revenue is expected to grow at 0.4% per year. EPS is expected to grow by 2.4% per annum.
Key information
-9.5%
Earnings growth rate
2.4%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 0.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Dec 15Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 75 | -133 | -23 | -145 | 6 |
12/31/2025 | 40 | -149 | -44 | -205 | 9 |
12/31/2024 | 184 | -42 | -56 | -59 | 7 |
9/30/2024 | 175 | -45 | -56 | -54 | N/A |
6/30/2024 | 141 | -72 | -47 | -44 | N/A |
3/31/2024 | 18 | -163 | -138 | -136 | N/A |
12/31/2023 | 60 | -114 | -146 | -141 | N/A |
9/30/2023 | 71 | -95 | -132 | -124 | N/A |
6/30/2023 | 71 | -91 | -145 | -127 | N/A |
3/31/2023 | 71 | -114 | -150 | -125 | N/A |
12/31/2022 | 27 | -165 | -172 | -142 | N/A |
9/30/2022 | 18 | -175 | -40 | -10 | N/A |
6/30/2022 | 12 | -176 | -29 | -7 | N/A |
3/31/2022 | 9 | -171 | -12 | 3 | N/A |
12/31/2021 | 6 | -158 | 2 | 11 | N/A |
9/30/2021 | 6 | -156 | -158 | -152 | N/A |
6/30/2021 | 6 | -149 | -129 | -124 | N/A |
3/31/2021 | 4 | -140 | -121 | -117 | N/A |
12/31/2020 | 4 | -130 | -56 | -54 | N/A |
9/30/2020 | 3 | -123 | -39 | -37 | N/A |
6/30/2020 | 2 | -127 | -52 | -50 | N/A |
3/31/2020 | 2 | -138 | -62 | -59 | N/A |
12/31/2019 | 1 | -137 | -116 | -113 | N/A |
9/30/2019 | 2 | -144 | -134 | -132 | N/A |
6/30/2019 | 42 | -99 | -96 | -92 | N/A |
3/31/2019 | 51 | -102 | -97 | -93 | N/A |
12/31/2018 | 60 | -96 | -109 | -104 | N/A |
9/30/2018 | 62 | -87 | -100 | -94 | N/A |
6/30/2018 | 49 | -93 | N/A | -91 | N/A |
3/31/2018 | 43 | -69 | N/A | -73 | N/A |
12/31/2017 | 38 | -70 | N/A | -54 | N/A |
9/30/2017 | 42 | -58 | N/A | -31 | N/A |
6/30/2017 | 17 | -76 | N/A | -59 | N/A |
3/31/2017 | 14 | -78 | N/A | -58 | N/A |
12/31/2016 | 14 | -72 | N/A | -48 | N/A |
9/30/2016 | 10 | -73 | N/A | -68 | N/A |
6/30/2016 | 12 | -61 | N/A | -53 | N/A |
3/31/2016 | 15 | -55 | N/A | -45 | N/A |
12/31/2015 | 14 | -48 | N/A | -32 | N/A |
9/30/2015 | 13 | -19 | N/A | -20 | N/A |
6/30/2015 | 10 | -37 | N/A | -30 | N/A |
3/31/2015 | 7 | -16 | N/A | -4 | N/A |
12/31/2014 | 4 | -12 | N/A | 24 | N/A |
9/30/2014 | 2 | -13 | N/A | 25 | N/A |
6/30/2014 | 1 | -12 | N/A | 37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADAP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADAP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADAP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADAP's revenue (0.4% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: ADAP's revenue (0.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADAP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 05:05 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adaptimmune Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Peter Lawson | Barclays |
Ying Huang | BofA Global Research |
Olga Smolentseva | Bryan Garnier & Co |